IIM
CADL icon

INTECH Investment Management’s Candel Therapeutics CADL Stock Holding History

INTECH Investment Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.8K Sell
11,787
-6,039
-34% -$32.9K ﹤0.01% 1990
2025
Q4 		$101K Sell
17,826
-2,722
-13% -$14.6K ﹤0.01% 2153
2025
Q3 		$105K Sell
20,548
-3,323
-14% -$19.2K ﹤0.01% 2246
2025
Q2 		$121K Sell
23,871
-4,695
-16% -$24.2K ﹤0.01% 2247
2025
Q1 		$161K Buy
+28,566
New +$233K ﹤0.01% 2169

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

INTECH Investment Management's CADL Position: Q1 2026 in Review

INTECH Investment Management reduced its Candel Therapeutics (CADL) stake by 34% in Q1 2026, selling an estimated $32.9K and leaving 11,787 shares worth $57.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

INTECH Investment Management first reported a position in CADL in Q1 2025 and has held it in 5 quarters since. The position peaked at $161K in Q1 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • INTECH Investment Management held 11,787 shares of Candel Therapeutics worth $57.8K as of Q1 2026.
  • INTECH Investment Management sold 6,039 Candel Therapeutics shares in Q1 2026, an estimated $32.9K.
  • Candel Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q1 2026, its #1990 holding.
  • INTECH Investment Management first reported a position in Candel Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • INTECH Investment Management's Candel Therapeutics position peaked at $161K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.